^(32)P-玻璃微球介入治疗肝细胞肝癌的临床初步应用

Preliminary clinical application of phosphorus-32 glass microspheres in interventional treating hepatocellular carcinoma

采用 Ｓｅｌｄｉｎｇｅｒｓ穿刺法，导管超选择至肝固有动脉以远，灌注^（３２）Ｐ－玻璃微球（^（３２）Ｐ－ＧＭＳ），对７９例肝细胞肝癌（ＨＣＣ）实施了９９次内照射介入治疗。结果表明，Ａ方案半年及１、２、３年生存率分别为１００％、９６．７％、５６．７％和４３．３％；Ｂ方案分别为９７．９％、９１８％、６１．２％和５１．０％。经治后的中位生存时间为５８５天。多因素分析显示：肝功能、肿瘤大小、临床类型及^（３２）Ｐ－ＧＭＳ在瘤体内积聚情况是影响生存率的预后因素。说明^（３２）Ｐ－ＧＭＳ是一种安全、有效的肝癌治疗方法。

To evaluate the therapeutic effect of phosphorus-32 glass microsphere (^(32)P-GMS) on hepatocellular carcinoma. By Seldinger's procedure, super-selective catheterization was performed to the distal end of proper hepatic artery for instilling ^(32)p-GMS. Ninety-nine times of interventional internal irradiation were accomplished in 79 cases of hepatocellular carcinoma. Results shows that surviving rates in A or B regimen at half year, 1, 2 and 3 years were 100%, 96.7%, 56.7% and 43.3% or 97.9%, 91.8%, 61.2% and 51.0% respectively. The median surviving time after therapy was 585 days single multifactorial analysis revealed liver function, tumor size, clinical typing and accumulation of ^(32)P-GMS in the tumor mass and the therapeutic regime were the prognostic factors influencing the surviving rate of the patient. Conclusion:^(32)P-GMS is a safe, effective and economic method for the therapeutic measure in treating hepatocellular carcinoma.